STOCK TITAN

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant

(Very Positive)
Tags

Royal Philips (NYSE: PHG) ranked No. 1 among medtech companies in the European Patent Office Technology Dashboard 2025 and remained the largest Dutch patent applicant with 1,289 European patent applications across domains and 676 Medtech filings in 2025. Philips invested > 9% of sales in R&D in 2025 and reported ~53,000 patent rights.

The company highlighted platform-based hardware, software, data and AI solutions and said its innovation improved the lives of 2 billion people in 2025, targeting 2.5 billion lives per year by 2030.

Loading...
Loading translation...

Positive

  • No.1 medtech ranking at the European Patent Office
  • 1,289 European patent applications across domains in 2025
  • Invested > 9% of sales in research and development in 2025
  • ~53,000 patent rights in intellectual property portfolio

Negative

  • Helium-free 3.0T MRI is a work in progress and not available in the US
  • Key innovations rely on AI and platform integration, which may face regulatory or deployment constraints

News Market Reaction – PHG

-0.30%
-0.30% Session close to close

In the Mar 24 session, PHG declined 0.30%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement emphasizes Philips’ innovation depth, with 1,289 European patent applications in 2...
Analysis

This announcement emphasizes Philips’ innovation depth, with 1,289 European patent applications in 2025 and more than 9% of sales invested in R&D. The company reports improving the lives of 2 billion people in 2025 and targets 2.5 billion annually by 2030, including 400 million in underserved communities. Historically, platform and AI-related news has produced mixed price reactions, so monitoring future product launches, adoption metrics, and margin trends around these innovations remains important.

Key Figures

Total EPO patent applications: 1,289 applications Medtech EPO patent filings: 676 applications Lives improved 2025: 2 billion people +5 more
8 metrics
Total EPO patent applications 1,289 applications European Patent Office filings in 2025 across various domains
Medtech EPO patent filings 676 applications Medical technology patent applications with EPO in 2025
Lives improved 2025 2 billion people Estimated people whose lives were improved in 2025
2030 lives target 2.5 billion people/year Goal for lives improved per year by 2030
Underserved target 400 million people/year Part of 2030 goal in medically underserved communities
R&D intensity More than 9% of sales Research and development investment in 2025
Patent portfolio 53,000 patent rights Size of Philips’ intellectual property portfolio
Top Innovator streak 13 consecutive years Clarivate Top 100 Global Innovator recognition

Historical Context

5 past events · Latest: Mar 23 (Neutral)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Mar 23 AGM announcement Neutral +2.1% AGM 2026 convened with board and CEO re-appointment items.
Mar 23 Board changes Neutral +2.1% New Supervisory Board appointment and multiple re-appointments including CEO.
Mar 17 Consumer marketing Positive +0.2% World Oral Health Night campaign highlighting Sonicare product performance.
Mar 11 Digital pathology Positive -0.5% Cloud-enabled IntelliSite Pathology Solution expansion on HealthSuite.
Mar 10 Platform showcase Positive -1.6% HIMSS26 presentation of interoperable, AI-enabled patient monitoring platforms.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news flow shows mixed price reactions: modest gains on governance and consumer-brand items, but occasional selloffs on seemingly positive digital and platform announcements.

Recent Company History

Over the past weeks, Philips has issued several operational and branding updates. On Mar 10, a connected care and HIMSS26 showcase saw a -1.6% move, followed by a digital pathology expansion on Mar 11 with a -0.48% reaction. A Sonicare marketing push on Mar 17 coincided with a small 0.18% gain. Governance-focused AGM and Supervisory Board announcements on Mar 23 both lined up with a stronger 2.13% move. Today’s innovation and patent-leadership story fits this broader emphasis on platform-based, AI-enabled health technology.

Key Terms

artificial intelligence, mri, image-guided therapy, ecg, +1 more
5 terms
artificial intelligence technical
"including patents related to artificial intelligence (AI) across its businesses."
Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.
mri medical
"Helium-free 3.0T MRI technology[1], advancing sustainability and precision"
Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.
image-guided therapy medical
"3D navigation solution for image-guided therapy, enabling physicians to visualize"
Image-guided therapy uses real-time medical images—like X-rays, CT, MRI or ultrasound—to steer treatments, procedures or device placement so clinicians can see what they are doing inside the body. For investors, it matters because these technologies can improve treatment accuracy, shorten procedures, reduce complications and create demand for specialized devices and software, which can drive revenue growth and influence regulatory and reimbursement outcomes.
ecg medical
"ECG AI Marketplace, which gives cardiac care teams access"
An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.
intense pulsed light medical
"the world’s No. 1 intense pulsed light hair removal brand Philips Lumea IPL"
Intense pulsed light (IPL) is a noninvasive medical device treatment that sends short bursts of broad-spectrum light into the skin to target pigmentation, blood vessels, hair follicles, or stimulate collagen. Think of it like a multiwavelength flashlight that selectively heats problem areas without cutting. Investors care because clinical results, safety profile, and regulatory clearance determine how widely clinics buy and use IPL systems, which drives manufacturers’ sales and recurring revenue for consumables and follow-up treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

March 24, 2026

  • Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025.
  • Philips’ platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges.
  • Philips’ innovation improved the lives of 2 billion people in 2025, with the goal of improving 2.5 billion lives per year by 2030, including 400 million people in medically underserved communities.

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it ranked No. 1 among medical technology companies in the European Patent Office’s (EPO) Technology Dashboard 2025. Medical technology is the most important domain for Dutch patent applications at the EPO. The ranking underscores the company’s continued leadership in health technology innovation. Philips filed 676 Medtech patent applications with the EPO in 2025, including patents related to artificial intelligence (AI) across its businesses. This reflects the company’s strong innovation pipeline focused on health technology solutions.

“Philips’ continued success as a top applicant with the European Patent Office reflects the strength of our innovation engine and our focus on meaningful innovation in healthcare and self-care,” said Marnix van Ginneken, Member of the Board of Management of Royal Philips. “Our innovation strategy is powered by data, AI and platform-based solutions to deliver better care for more people.”

Our customer- and consumer-centric innovation and platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges. By securely connecting data from imaging systems, patient monitors and connected devices across care settings from hospitals to the home, Philips helps clinicians make better decisions and deliver more efficient care. Through collaborations with clinical, technology and customer partners, Philips brings new healthcare solutions to market faster and at scale.

Philips’ innovation improved the lives of 2 billion people in 2025. By 2030, we aim to improve the lives of 2.5 billion people per year, including 400 million people in medically underserved communities.

Examples of Philips’ recent innovations include:

  • Helium-free 3.0T MRI technology[1], advancing sustainability and precision in diagnostic imaging. Using SmartSpeed Precise with Integrated Dual AI, MR scans can be delivered up to three times faster with up to 80% sharper images.
  • Philips’ flagship spectral CT system Verida, featuring Spectral Precision Image technology to deliver sharper and more conclusive diagnostic insights in a single scan, and Rembra CT, designed to set a new benchmark for speed and patient access in acute and high-demand imaging environments.
  • LumiGuide 3D Device Guidance, the world’s first real-time AI-enabled, light-based 3D navigation solution for image-guided therapy, enabling physicians to visualize and guide devices inside the body using light instead of continuous X-ray.
  • ECG AI Marketplace, which gives cardiac care teams access to multiple vendor offerings in one place, enabling clinicians to deploy and manage AI-powered diagnostic tools more easily.
  • Innovation for consumers such as the AI-powered i9000 Shaver Series; the world’s No. 1 intense pulsed light hair removal brand Philips Lumea IPL; and the Avent Hands-Free Breast Pump designed using more than 40 years of breastfeeding research.

In total, Philips contributed 1,289 European patent applications across various domains, remaining the largest Dutch applicant. The EPO ranking adds to Philips’ broader recognition for innovation leadership. Earlier this year, Philips was named a Clarivate Top 100 Global Innovator for the 13th consecutive year. In 2025, Philips invested more than 9% of sales in research and development, an industry-leading standard. Philips’ intellectual property portfolio includes approximately 53,000 patent rights, 31,500 trademarks, 159,000 design rights and 3,100 domain names.

[1] Helium-free 3.0T MRI is Work in Progress and not available in the US or any jurisdiction. Its future availability cannot be guaranteed.

For further information, please contact:

Michael Fuchs
Philips Global External Relations
Tel.: +31 614869261
E-mail: Michael.Fuchs@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments


FAQ

Why did Royal Philips (PHG) rank No.1 in the EPO Technology Dashboard 2025?

Because Philips filed a high volume of patent applications with the EPO in 2025, including 1,289 total filings. According to the company, 676 of those filings were in Medtech, supporting its top ranking among medical technology applicants.

How many European patent applications did Philips (PHG) file in 2025?

Philips filed 1,289 European patent applications across domains in 2025. According to the company, 676 of those applications were specifically in Medtech, contributing to its position as the largest Dutch applicant at the EPO.

What R&D investment level did Philips (PHG) report for 2025?

Philips invested more than 9% of sales in research and development in 2025. According to the company, this represents an industry-leading standard supporting its innovation pipeline and platform-based health technology solutions.

What product innovations did Philips highlight in the March 24, 2026 announcement?

Philips highlighted helium-free 3.0T MRI, Verida spectral CT, LumiGuide 3D Device Guidance and ECG AI Marketplace. According to the company, these span imaging, AI-enabled guidance and diagnostic AI access for clinicians.

Is Philips' helium-free 3.0T MRI available in the US now?

No, the helium-free 3.0T MRI is described as a work in progress and not available in the US. According to the company, its future availability cannot be guaranteed at this time.

How many people did Philips say its innovation reached in 2025 and what is the 2030 target?

Philips said its innovation improved the lives of 2 billion people in 2025 and aims for 2.5 billion people per year by 2030. According to the company, this target includes 400 million in underserved communities.